Therapeutic management of PI3Kα inhibitor-induced hyperglycemia with a novel glucokinase activator: Advancing the Frontier of PI3Kα inhibitor therapy
Dorzagliatin shows promise for managing PI3Ki-associated hyperglycemia, thereby enhancing its therapeutic efficacy. The activation of liver glycogen kinase and insulin regulation may be key mechanisms underlying its therapeutic benefits.
Authors
- Yu Kang (ORCID: https://orcid.org/0000-0002-8706-3252)
- Xiaobo Cheng
- Ai Huang (ORCID: https://orcid.org/0000-0001-7796-5343)
- Wei Wei (ORCID: https://orcid.org/0000-0002-3117-9598)
- Yongguo Li (ORCID: https://orcid.org/0000-0003-4887-1414)
- Wei Ye (ORCID: https://orcid.org/0000-0001-6613-1976)
- Yi Huan (ORCID: https://orcid.org/0000-0002-4444-3941)
- Kewei Zheng (ORCID: https://orcid.org/0009-0002-5479-2544)
- Shihuang Liu
- Guiling Li
- Ranran Chai
- Guanqin Jin (ORCID: https://orcid.org/0000-0001-8104-5718)
Institutions
- Fujian Medical University (CN)
- ShanghaiTech University (CN)
- Fujian Women and Children Hospital (CN)
- Wuhan Union Hospital (CN)
- Obstetrics and Gynecology Hospital of Fudan University (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Molecular Metabolism
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1016/j.molmet.2025.102151
- Citations
- 2
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.61